Literature DB >> 20956939

MicroRNA-101-mediated Akt activation and estrogen-independent growth.

M Sachdeva1, H Wu, P Ru, L Hwang, V Trieu, Y-Y Mo.   

Abstract

MicroRNAs are gene regulators that work through a posttranscriptional repression mechanism. Dysregulation of microRNA expression could lead to a variety of disorders, in particular, human cancer, and has also been implicated in antihormone therapy resistance. However, little is known whether microRNAs have a role in estrogen-independent growth, leading to tamoxifen resistance in estrogen receptor (ER)-positive tumors. In this study, we use an in vivo selection system against a microRNA library using the MCF-7 model and demonstrate that miR-101 promotes estrogen-independent growth and causes the upregulation of phosphorylated Akt (pAkt) without impacting the ER level or activity. Importantly, although miR-101 suppresses cell growth in normal estradiol (E2)-containing medium, it promotes cell growth in E2-free medium. Moreover, estrogen deprivation greatly enhances miR-101-mediated Akt activation. Finally, we show that MAGI-2 (membrane-associated guanylate kinase), a scaffold protein required for PTEN (phosphatase and tensin homolog) activity, is a direct target for miR-101; suppression of MAGI-2 by miR-101 reduces PTEN activity, leading to Akt activation. Taken together, these results not only establish a role for miR-101 in estrogen-independent signaling but also provide a mechanistic link between miR-101 and Akt activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956939     DOI: 10.1038/onc.2010.463

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  52 in total

Review 1.  MicroRNAs in autophagy and their emerging roles in crosstalk with apoptosis.

Authors:  Jianzhen Xu; Yanfei Wang; Xiaorong Tan; Hongjuan Jing
Journal:  Autophagy       Date:  2012-03-23       Impact factor: 16.016

Review 2.  Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.

Authors:  Stéphanie Bianco; Nicolas Gévry
Journal:  Transcription       Date:  2012-07-01

3.  Epigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182.

Authors:  Mohit Sachdeva; Rebecca D Dodd; Zhiqing Huang; Carole Grenier; Yan Ma; Dina C Lev; Diana M Cardona; Susan K Murphy; David G Kirsch
Journal:  Cancer Lett       Date:  2015-08-24       Impact factor: 8.679

4.  MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma.

Authors:  Ying Liu; Haiyan Li; Congying Zhao; Hanbing Jia
Journal:  Mol Cell Biochem       Date:  2018-02-05       Impact factor: 3.396

5.  ES cells overexpressing microRNA-1 attenuate apoptosis in the injured myocardium.

Authors:  Carley Glass; Dinender K Singla
Journal:  Mol Cell Biochem       Date:  2011-06-14       Impact factor: 3.396

6.  Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer.

Authors:  Reza Mahdian; Vahideh Nodouzi; Mojgan Asgari; Mitra Rezaie; Javad Alizadeh; Behzad Yousefi; Hossein Shahrokh; Maryam Abolhasani; Mohamadreza Nowroozi
Journal:  Mol Biol Rep       Date:  2014-07-02       Impact factor: 2.316

Review 7.  The novel role of miRNAs for tamoxifen resistance in human breast cancer.

Authors:  Wenwen Zhang; Jing Xu; Yaqin Shi; Qian Sun; Qun Zhang; Xiaoxiang Guan
Journal:  Cell Mol Life Sci       Date:  2015-03-18       Impact factor: 9.261

Review 8.  miRNAs and estrogen action.

Authors:  Carolyn M Klinge
Journal:  Trends Endocrinol Metab       Date:  2012-04-11       Impact factor: 12.015

9.  The miR-101/RUNX1 feedback regulatory loop modulates chemo-sensitivity and invasion in human lung cancer.

Authors:  Xianghui Wang; Yihua Zhao; Haiyun Qian; Jiangping Huang; Fenghe Cui; Zhifu Mao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 10.  MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications.

Authors:  Wei Tian; Junqing Chen; Haifei He; Yongchuan Deng
Journal:  Clin Transl Oncol       Date:  2012-08-23       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.